E-LIB Suche - Ergebnisse für: GARRISON, MARK W.

1

Ceftolozane-tazobactam activity against clinical isolates o..:

Pfaller, Michael A. ; Shortridge, Dee ; Harris, Kelly A....
International Journal of Infectious Diseases. 112 (2021) - p. 321-326 , 2021

Link: https://doi.org/10.1016/..

2

Can Flush and Lock Solutions Used in Human Medicine Be Appl..:

Leonard, James ; Skaer, Tracy L. ; Garrison, Mark W.
Journal of Equine Veterinary Science. 34 (2014) 7 - p. 837-841 , 2014

Link: https://doi.org/10.1016/..

3

Antibiotic Collateral Damage: Resistance and Antibiotic-Ass..:

Matsuura, Gregory T. ; Garrison, Mark W.
Hospital Pharmacy. 46 (2011) 10 - p. 758-768 , 2011

Link: https://doi.org/10.1310/..

4

In vitro activity of tigecycline and comparator agents agai..:

Garrison, Mark W. ; Mutters, Reinier ; Dowzicky, Michael J.
Diagnostic Microbiology and Infectious Disease. 65 (2009) 3 - p. 288-299 , 2009

Link: https://doi.org/10.1016/..

5

In vitro activity of tigecycline against quinolone-resistan..:

Garrison, Mark W. ; Nuemiller, Joshua J.
International Journal of Antimicrobial Agents. 29 (2007) 2 - p. 191-196 , 2007

Link: https://doi.org/10.1016/..

6

Antibiotic Selection and Resistance Issues with Fluoroquino..:

Brouillard, Jason E. ; Terriff, Colleen M. ; Tofan, Andreea.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 26 (2006) 1 - p. 3-14 , 2006

Link: https://doi.org/10.1592/..

7

Pharmacodynamic assessment of the activity of high-dose (75..:

Garrison, Mark W.
Diagnostic Microbiology and Infectious Disease. 54 (2006) 1 - p. 51-56 , 2006

Link: https://doi.org/10.1016/..

8

Tigecycline: An investigational glycylcycline antimicrobial..:

Garrison, Mark W. ; Neumiller, Joshua J. ; Setter, Stephen M.
Clinical Therapeutics. 27 (2005) 1 - p. 12-22 , 2005

Link: https://doi.org/10.1016/..

9

In vitro pharmacodynamic activity of gatifloxacin, gemiflox..:

Garrison, Mark W. ; Schimmels, Julie A. ; Madaras-Kelly, Karl J.
Diagnostic Microbiology and Infectious Disease. 47 (2003) 4 - p. 587-593 , 2003

Link: https://doi.org/10.1016/..

10

Comparison of various in vitro susceptibility methods for t..:

Carroll, Karen C ; Cohen, Samuel ; Nelson, Ryan...
Diagnostic Microbiology and Infectious Disease. 32 (1998) 3 - p. 229-235 , 1998

Link: https://doi.org/10.1016/..

11

Levofloxacin: a therapeutic review:

Wimer, Steven M. ; Schoonover, Lori ; Garrison, Mark W.
Clinical Therapeutics. 20 (1998) 6 - p. 1049-1070 , 1998

Link: https://doi.org/10.1016/..

12

Protease inhibitors: a therapeutic breakthrough for the tre..:

Lewis II, James S. ; Terriff, Colleen M. ; Coulston, Daniel R..
Clinical Therapeutics. 19 (1997) 2 - p. 187-214 , 1997

Link: https://doi.org/10.1016/..

13

Influence of pH on the antimicrobial activity of clarithrom..:

Garrison, Mark W. ; Malone, Connie L. ; Eiland, John.
Diagnostic Microbiology and Infectious Disease. 27 (1997) 4 - p. 139-145 , 1997

Link: https://doi.org/10.1016/..

14

Comparative activity of temafloxacin, ofloxacin, and ciprof..:

Garrison, Mark W. ; Campbell, Douglas M. ; Sclar, David A..
Current Therapeutic Research. 55 (1994) 12 - p. 1432-1441 , 1994

Link: https://doi.org/10.1016/..

15

Identifying and Treating Common and Uncommon Infections in ..:

Garrison, Mark W. ; Campbell, R. Keith
The Diabetes Educator. 19 (1993) 6 - p. 522-529 , 1993

Link: https://doi.org/10.1177/..